## Core Concept
Multiple myeloma is a type of hematological malignancy characterized by the proliferation of malignant plasma cells in the bone marrow. The prognosis of multiple myeloma is determined by various factors, including genetic abnormalities, clinical features, and laboratory parameters. Understanding these prognostic factors is crucial for guiding treatment decisions and predicting patient outcomes.

## Why the Correct Answer is Right
Option is the correct answer because represents a factor that is not typically associated with a poor prognosis in multiple myeloma. The common poor prognostic factors in multiple myeloma include high levels of beta-2 microglobulin, presence of certain genetic abnormalities like deletion 17p or t(14;16), high plasma cell proliferation rate, and elevated levels of lactate dehydrogenase (LDH).

## Why Each Wrong Option is Incorrect
* **Option A:** is a poor prognostic factor because it indicates a higher tumor burden and aggressive disease.
* **Option B:** represents another poor prognostic factor, as it signifies a specific genetic abnormality associated with a worse outcome.
* **Option C:** is also a poor prognostic factor, reflecting increased disease activity and proliferation.

## Clinical Pearl / High-Yield Fact
A key clinical pearl in multiple myeloma is the importance of cytogenetic analysis, particularly for detecting high-risk genetic abnormalities such as deletion 17p, t(14;16), and t(4;14), which significantly impact prognosis and guide therapeutic decisions.

## Correct Answer: D.